SCM
PBYI icon

Suvretta Capital Management’s Puma Biotechnology PBYI Stock Holding History

Suvretta Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-71,500
Closed -$603K – 99
2020
Q1 		$603K Buy
+71,500
New +$695K 0.02% 59

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Suvretta Capital Management's PBYI Position: Q2 2020 in Review

Suvretta Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2020, closing a stake of 71,500 shares — an estimated $603K sold.

Suvretta Capital Management first reported a position in PBYI in Q1 2020 and held it in 1 quarter. The position peaked at $603K in Q1 2020. 128 funds tracked by Wall St. Rank hold PBYI as of Q2 2020.

  • Suvretta Capital Management reported no remaining Puma Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 71,500 Puma Biotechnology shares in Q2 2020, an estimated $603K.
  • Suvretta Capital Management first reported a position in Puma Biotechnology in Q1 2020 and held it in 1 quarter.
  • Suvretta Capital Management's Puma Biotechnology position peaked at $603K in Q1 2020.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2020.

Based on Suvretta Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.